| Company Name: | Ziopharm Oncology, Incorporated | | Ticker Symbol: | ZIOP | | | WWW Address: | www.ziopharm.com | | CEO: | Dr. Jonathan Lewis, M.D., Ph.D. | | No. of Employees: | 17 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company that is seeking to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs that address unmet medical needs.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 3.67 |  0.14 | 2.72 | 4.55 | 3.45 | 3.69 | 3.40 | 162001 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 94.0 | 25.6 | 1.05 | -1.19 | 0.00 | 0.0 | 0.0 | 4.10 - 0.50 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 3.67 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 93.8 | mil |
| Latest Shares Outstanding | 25.6 | mil |
| Earnings pS (EPS) | -1.19 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 0 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 20.6 | mil |
| Float as % of Shares Outstanding | 94.5 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -162.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -335.9 | % |
| Current Ratio | 2.1 | |
| Leverage Ratio (Assets/Equity) | 2.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.15 | $ |
| Cash pS | 0.28 | $ |
| Book-Value pS | 0.15 | $ |
| Tangible Book-Value pS | 0.15 | $ |
| Cash Flow pS | -0.50 | $ |
| Free Cash Flow pS | -0.50 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 23.92 | |
| Price/Tangible Book Ratio | 23.92 | |
| Price/Cash Flow | -7.3 | |
| Price/Free Cash Flow | -7.4 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.9 | 101 | 1,547 | 2,718 |
| 4 Weeks | 3.95 | 2.91 | 3.21 | 14.3 | 107 | 2,153 | 36,601 |
| 13 Weeks | 4.10 | 1.50 | 1.55 | 136.8 | 220 | 2,133 | 130,088 |
| 26 Weeks | 4.10 | 1.25 | 1.62 | 126.5 | 188 | 1,333 | 166,667 |
| 52 Weeks | 4.10 | 0.50 | 0.97 | 278.4 | 307 | 825 | 205,405 |
| YTD | 4.10 | 0.50 | - | 532.8 | 517 | 865 | 196,418 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 3.54 | 3.57 | 3.13 | 2.05 | 1.66 | 1.05 | 1.28 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 8.06 |
| R&D | 0.00 | NA | -1.14 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.57 | 0.13 | 0.22 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 47.16 |
| Current Ratio | 2.0 |
| Quick Ratio (Acid Test) | 2.0 |
| Liquidity Ratio (Cash) | 1.97 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 88.0 |
| Working Capital pS | 0.27 |
| Cash-Flow pS | -1.14 |
| Free Cash-Flow pS | -1.08 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.79 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 46.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.9 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.08 |
| Tobin's Q Ratio | 7.46 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.50 |
| Enterprise Value (EV)/Free Cash Flow | -3.49 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 23.92 |
| Price/Book Ratio - LTM | 23.92 |
| Price/Cash Flow Ratio | -7.3 |
| Price/Free Cash Flow Ratio - LTM | -7.4 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.26 |
| Tangible Book Value pS - LTM | 0.15 |
| Book Value pS - LTM | 0.15 |
| Capital Invested pS | 0.26 |
| Cash pS - LTM | 0.28 |
| Cash Flow pS - LTM | -0.50 |
| Free Cash Flow pS - LTM | -0.50 |
| Earnings pS (EPS) | -1.19 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | 0.00 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -374.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -111.9 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -200.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | -89.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 0 |
| Net Income per Employee | -1,484,176 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 0.00 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |